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We studied genes involved in pancreatic β cell function and survival, identifying associations
between SNPs in WFS1 and diabetes risk in UK populations that we replicated in an Ashkenazi
population and in additional UK studies. In a pooled analysis comprising 9,533 cases and 11,389
controls, SNPs in WFS1 were strongly associated with diabetes risk. Rare mutations in WFS1
cause Wolfram syndrome; using a gene-centric approach, we show that variation in WFS1 also
predisposes to common type 2 diabetes.
Progressive deterioration in β cell function is central to the pathophysiology of type 2
diabetes. Indeed, genes with important roles in pancreatic β cells have been shown to
influence susceptibility to type 2 diabetes, including KCNJ11 (refs. 1,2), HNF4A (refs. 3,4)
and, most recently, TCF7L2 (ref. 5). Therefore, we conducted a gene-centric association
study for type 2 diabetes, genotyping 1,536 SNPs in 84 genes regulating pancreatic β cell
development, growth, function and survival (Supplementary Methods online). We
genotyped all 1,536 SNPs in four case-control studies of type 2 diabetes (three UK and one
Ashkenazi population) and used a two-stage analysis (Supplementary Methods). Informed
written consent was obtained from all study participants, and all studies were approved by
the relevant ethics committees (Supplementary Methods).
We first assessed the association between candidate SNPs and diabetes risk in the three UK
study sets, comprising up to 1,484 cases and 1,856 controls, using a log-additive
(codominant) model. Of 1,367 SNPs that passed genotyping quality control (Supplementary
Methods), 18 (1.3%) were associated with diabetes risk at P < 0.01, our threshold for
defining association in this initial screening phase (Table 1 and Supplementary Table 1
online). In the second phase, to reduce the number of statistical tests, we restricted the
analysis to assessing the association between these 18 SNPs and diabetes risk in the
Ashkenazim study set, an ethnically distinct founder population comprising 930 cases and
461 controls. Two of the originally associated SNPs (rs10010131 and rs6446482) were
associated in this independent study at P < 0.05 (Table 1).
As expected, the two replicated SNPs (rs10010131 and rs6446482) were associated with
diabetes risk in a combined analysis of all four studies (P = 1.3 × 10-4 and P = 2.7 × 10-4,
respectively; Supplementary Table 2 online). These SNPs were in strong LD with each other
in our study populations (r2 = 0.98) and located in the same gene, WFS1. For rs10010131
and rs6446482, the risk allele was the major allele, with a frequency of 60% for both SNPs.
Although only two of the original six variants typed across WFS1 were associated with
diabetes in our two-staged approach, in a pooled analysis of all four study sets, five SNPs
showed statistical association (Supplementary Table 2). This was not unexpected, given the
high linkage disequilibrium (LD) among these SNPs (Supplementary Table 3 online).
Compared with the other WFS1 SNPs, rs10010131 showed a marginally stronger
association. Therefore, we used likelihood ratio tests (Supplementary Methods and
Supplementary Table 4 online) to assess whether rs10010131 explained all the observed
associations. Based on these analyses, we found that all the association signals were due to
rs10010131 and rs6446482. We also found evidence of possible interdependency between
these SNPs and rs752854 on disease risk (Supplementary Table 4). Because of their high
correlation, these analyses suggest that rs10010131 or rs6446482 might be independent
causal alleles, or that they are in LD with a causal allele, or both, and that the other SNPs do
not independently contribute to disease risk.
The SNPs showing independent associations or interdependency (rs10010131, rs6446482
and rs752854) are intronic, with no obvious evidence for biological function. Therefore, we
conducted a more detailed examination of variation in this gene. Using data from HapMap,
and based on sequence spanning 63.4 kb (chromosome 4, 6374656-6438055), including 15
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kb extending both 5′ and 3′ from WFS1, we detected strong LD across the region. The
entire gene was defined by a single haplotype block of 39 kb (Supplementary Fig. 1 online).
Within this block, 53 SNPs had a minor allele frequency (MAF) of ≥1%. The six SNPs we
typed in our studies were all located in this region and together tagged 88% of the common
variation in this block (47 of the 53 SNPs, MAF ≥1%, r2 ≥ 0.8) with a mean r2 of 0.97. One
nonsynonymous SNP (R611H, rs734312) is highly correlated with SNPs rs10010131 (r2 =
0.92) and rs6446482 (r2 = 0.88) and thus may be a causal variant. Consistent with this LD
structure, a previous study based on 479 cases and 509 controls (a subset of our samples) has
shown suggestive association between rs734312 and type 2 diabetes6.
To extend support for an association between variation at WFS1 and diabetes risk, we
attempted further replication, typing rs10010131, rs6446482, rs752854 and the highly
correlated nonsynonymous SNP (rs734312) in three further case-control studies,
ADDITION (926 cases and 1,497 controls), Warren 2 (2,465 cases and 3,843 controls) and
Tayside (3,728 cases and 3,732 controls). For rs10010131, rs6446482 and rs752854, we
found independent evidence for association in each study (Table 2).
Because of the possible interdependency between rs10010131 and rs752854 in the
secondary analysis of the four initial studies, we assessed this association in a combined
analysis of the ADDITION, Warren 2 and Tayside studies. We did not find any evidence for
interdependency in these studies (data not shown). We also conducted haplotype analysis
using log-linear modeling. Based on these two loci, we did not find any consistent evidence
for a haplotype association that was independent of the underlying SNP associations among
these studies (data not shown).
We also found some evidence for association of the nonsynonymous SNP rs734312 in the
ADDITION, Warren 2 and Tayside studies (Table 2). Therefore, we genotyped this variant
in our original studies and conducted a pooled analysis of all seven studies, comprising up to
9,533 cases and 11,389 controls (Table 2). In this analysis, rs734312 was associated with
diabetes risk (P = 2.0 × 10-5). However, likelihood ratio tests showed that rs734312 did not
contribute to a model including rs10010131 (P = 0.88), whereas rs10010131 substantially
improved the fit of a model including rs734312 (P = 4.9 × 10-3), suggesting that rs734312 is
unlikely to be the functional variant explaining these associations. We also did not find any
consistent evidence for interdependency between rs10010131 or rs6446482 and rs752854
and diabetes risk in the combined study sets (data not shown).
By contrast, we found that rs10010131 (MAF = 40%) and rs6446482 (MAF 41%) were
strongly associated with diabetes risk at P = 1.4 × 10-7 and P = 3.4 × 10-7, respectively, in
the pooled study set (Table 2). Furthermore, the magnitude of this association was highly
consistent across studies (Supplementary Fig. 2 and Supplementary Table 5 online), with no
heterogeneity among studies (P (six degrees of freedom) = 0.59 and 0.68 for rs10010131
and rs6446482, respectively).
We provide strong evidence for an association between variation at WFS1 and risk of type 2
diabetes. WFS1 encodes wolframin, a membrane glycoprotein that maintains calcium
homeostasis of the endoplasmic reticulum. Mutations in this gene cause Wolfram syndrome
(DIDMOAD, OMIM 222300), which is characterized by diabetes insipidus, juvenile-onset
non-autoimmune diabetes mellitus, optic atrophy and deafness7,8. Disruption of Wfs1 in
mice causes overt diabetes or impaired glucose tolerance, depending on genetic
background9,10. Both humans and mice deficient in Wolframin show pancreatic β cell loss,
possibly as a result of an enhanced endoplasmic reticulum stress response leading to
increased β cell apoptosis9,11,12. Thus, WFS1 is critical for survival and function of
insulin-producing pancreatic β cells. In line with this evidence, chemical enhancement of
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endoplasmic reticulum function has been suggested as a treatment for the metabolic
abnormalities associated with diabetes13.
Our results indicate that variation in WFS1 not only results in a rare syndrome partly
characterized by early-onset non-autoimmune diabetes but also is associated with
susceptibility to common type 2 diabetes. For rs10010131, based on a risk allele frequency
of 60%, we estimate that the population attributable fraction is 9%, explaining 0.3% of the
excess familial risk. Other examples of such polygenic loci that are also involved in
monogenic and syndromic forms of type 2 diabetes include KCNJ11 (ref. 1), PPARG14 and
HNF4A3,4.
Our study demonstrates that with sufficiently powered studies, the gene-centric approach is
an effective strategy to identify disease susceptibility loci that contribute modest risk,
complementing genome-wide approaches. Because of strong LD across WFS1 in European
populations and the difficulty of resolving association signals in an epidemiological context,
our study also highlights the need for appropriately powered studies in populations with
greater genetic diversity. In conclusion, these data provide strong evidence that variation in
WFS1, a gene with an essential role in the endoplasmic reticulum stress response in insulin-
producing pancreatic β cells, contributes to risk of common type 2 diabetes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Association between SNPs located in WFS1 and risk of type 2 diabetes: replication studies
and pooled analysis
SNP Odds ratio (95% c.i.) P value
ADDITION study (926 cases, 1,497 controls)
rs10010131 0.87 (0.77-0.98) 0.020
rs6446482 0.87 (0.77-0.98) 0.021
rs752854 0.86 (0.76-0.97) 0.013
rs734312 0.92 (0.82-1.03) 0.163
Warren 2 study (2,465 cases, 3,843 controls)
rs10010131 0.91 (0.84-0.98) 0.011
rs6446482 0.92 (0.86-0.99) 0.027
rs752854 0.93 (0.86-1.00) 0.060
rs734312 0.93 (0.87-1.00) 0.061
Tayside study (3,728 cases, 3,732 controls)
rs10010131 0.93 (0.87-0.99) 0.029
rs6446482 0.92 (0.87-0.99) 0.019
rs752854 0.93 (0.86-0.99) 0.032
rs734312 0.93 (0.87-0.99) 0.019
All seven pooled studies, comprising up to 9,533 cases and 11,389 controlsa
rs10010131 0.90 (0.86-0.93) 1.4 × 10-7
rs6446482 0.90 (0.87-0.94) 3.4 × 10-7
rs734312 0.92 (0.88-0.95) 2.0 × 10-5
rs752854 0.92 (0.88-0.96) 1.3 × 10-4
c.i., confidence interval. Boldface represents replicated SNPs.
a
Based on a single-locus log-additive model adjusted for study.
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